Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • Publications
  • In the News

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting

Oct 9, 2020

Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange

Sep 28, 2020

Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Sep 8, 2020

Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation

Sep 2, 2020

Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference

Aug 24, 2020

Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results

Aug 13, 2020

Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership

Aug 10, 2020

Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma

Aug 10, 2020

Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update

Aug 6, 2020

Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)

Jun 15, 2020
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...43
    © 2023 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap